The formyl peptide receptor (FPR) couples to pertussis toxin (PTX)-sensitive G i -proteins to activate chemotaxis and exocytosis in neutrophils. PTX reduces not only formyl peptide-stimulated but also agonist-independent ("basal") G i -protein activity, suggesting that the FPR is constitutively active. We aimed at identifying an inverse FPR agonist, i.e. a compound that suppresses constitutive FPR activity. In Sf9 insect cell membranes, the G-protein heterotrimer 
Human neutrophils play a key role in host defense against bacterial infections (1-3). Neutrophils are activated by the bacterial formyl peptide N-formyl-L-methionyl-L-leucyl-L-phenylalanine (FMLP).
1 FMLP binds to a specific formyl peptide receptor (FPR) that initiates a complex signaling cascacde ultimately resulting in chemotaxis and the release of cytotoxic products such as reactive oxygen species and lysosomal enzymes (1) (2) (3) . The FPR belongs to the chemoattractant receptor family that is part of the superfamily of G-protein-coupled receptors (GPCRs) (4, 5) . The FPR couples to the pertussis toxin (PTX)-sensitive G-proteins G i2 and G i3 (6, 7) . The stimulatory effects of FMLP are blocked by the competitive FPR antagonists N-t-butoxycarbonyl-L-phenylalanyl-L-leucyl-L-phenylalanyl-L-leucyl-L-phenylalanine (BocPLPLP) and cyclosporin H (CsH) (8 -11) . BocPLPLP is a synthetic linear peptide analogue of FMLP (9) , and CsH is a cyclic undecapeptide from the fungus Tolyplocadium inflatum Gams (12) . Chemically, CsH is a stereoisomer of the immunosuppressant drug cyclosporin A (13) , but cyclosporin A is not an FPR antagonist (10, 11) .
The two-state model of GPCR activation assumes that GPCRs exist in an inactive ("R") state or an active ("R*") state (14 -16) . According to this model, the isomerization of GPCR from R to R* can occur, to some extent, also in the absence of agonist which process is referred to as constitutive activity. Agonists stabilize the R* state and increase basal G-protein activity. However, since GPCRs can isomerize from R to R* even agonist-independently, the basal G-protein activity actually does not reflect the intrinsic basal activity of the G-protein but rather basal GPCR activity. Inverse agonists stabilize the R state and decrease basal G-protein activity. Neutral antagonists do not affect the equilibrium between R and R* and block both agonist and inverse agonist effects. In addition to agonists, G-proteins can stabilize the R* state (17, 18) .
Many wild-type GPCRs including the ␤ 2 -adrenoreceptor (19 -21) , the 5-hydroxytryptamine 2C receptor (22) , the histamine H 2 receptor (23), the ␦-opioid receptor (24) , the thyrotropin receptor (25) and the ␣ 2D -adrenoreceptor (26) are constitutively active. The absolute expression levels of GPCR and G-proteins and their relative stoichiometry to each other determine the sensitivity with which constitutive activity is detected. Specifically, at a low GPCR expression level, a given compound may appear to act as neutral antagonist, whereas at high GPCR and/or G-protein expression levels, the compound may behave as inverse agonist (17, 20, 21, 27, 28) .
Circumstantial evidence suggests that the FPR is constitutively active as well. In particular, PTX inhibits not only the FMLP-induced G i -protein activation but also reduces the basal G i -protein activity in membranes of myeloid differentiated HL-60 cells (29 -31) . Additionally, Na ϩ efficiently reduces basal G-protein activity in membranes expressing G i -protein-linked constitutively active GPCRs (26, 32) and in myeloid membranes expressing FPR (29, 30) .
We hoped to identify an inverse FPR agonist to validate the assumed constitutive activity of the FPR. To achieve this aim, we took advantage of the Spodoptera frugiperda (Sf9) insect cell expression system. The Sf9 cell system provides a low background of endogenous G-proteins (17, 33, 34) and is highly sensitive at unmasking constitutive activity of GPCRs, provided that the appropriate complement of G-proteins is expressed (17, 20, 21, (35) (36) (37) . Ye and colleagues (37) have already shown that the human FPR can be expressed in Sf9 cells. Of interest, Sf9 cells do not endogenously express G i -proteins to efficiently support G-protein-coupling of the FPR. Therefore, * The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. (Campbell, CA) . All other reagents were of the highest purity available and were from standard suppliers.
Construction of FLAG Epitope-and Hexahistidine-tagged Modified FPR-DNA-The FPR, like most GPCRs, is a type IIIb membrane protein with an extracellular N terminus without a signal sequence. Adding a signal sequence to the N terminus serves to direct the membrane insertion of proteins cotranslationally (43) and enhances the production of functional GPCR protein in insect cells (44) . Therefore, a DNA sequence encoding the cleavable signal peptide from influenza hemagglutinin followed by the FLAG epitope, which can be recognized by the M1 antibody, was placed 5Ј of the start codon of the DNA of FPR-26. We also added a hexahistidine tag to the FPR C terminus to allow future purification of the receptor and to provide additional protection against proteolysis (45, 46) . The FPR modifications were generated by sequential overlap-extension PCRs using Pfu polymerase (Stratagene, La Jolla, CA). In PCR 1A, the DNA sequence of the signal peptide (S) and the FLAG epitope (F) was amplified with pGEM-3Z-SF-h␤ 2 -adrenoreceptor-6His (20) as template by using a sense primer 5Ј of the SacI site near the SF sequence (sense pGEM primer) and an antisense primer encoding the last 19 bp of the SF. In PCR 1B, the cDNA of FPR-26 was amplified using pCDM8-FPR-26 as template with a sense primer which annealed with the first 17 bp of the 5Ј-end of the FPR and included the last 19 bp of the SF in its 5Ј-extension. The antisense primer encoded amino acids 331-348 of the FPR with a silent mutation in the triplet of Thr-336 (ACC 3 ACG). Thereby, we introduced a unique EcoRI site for diagnostic purposes and future cloning procedures. In PCR 2, the products of PCRs 1A and B were used as templates. The sense pGEM primer and an antisense primer, annealing with the last 15 bp of the 3Ј-end of PCR product 1B and having an extension that encodes the two Cterminal amino acids of FPR-26, a hexahistidine tag, the stop codon, and an extra XbaI site for cloning purposes, were used to prime PCR 2. In this way, a fragment encoding the signal sequence, the FLAG epitope, FPR-26 cDNA, and a hexahistidine tag followed by an XbaI site was obtained. This fragment was digested with SacI and XbaI and cloned into pGEM-3Z-SF-h␤ 2 -adrenoreceptor-6His digested with SacI and SalI together with a linker oligonucleotide encoding (5Ј to 3Ј) an XbaI site, a BamHI site, and a SalI site. PCR-generated DNA sequences were confirmed by enzymatic sequencing using Sequenase version 2.0 Sequencing kit (U. S. Biochemical Corp.). The cDNA encoding the FLAG epitope-and hexahistidine-tagged FPR was cloned into the baculovirus expression vector pVL 1392 and the mammalian expression vector pcDNA 3.0 using the HindIII site at the 5Ј-end of the SF region and the XbaI site at the 3Ј-end of the receptor.
Generation of Recombinant Baculoviruses and Cell Culture and Membrane Preparation-Recombinant baculovirus encoding FPR was generated in Sf9 cells using the BaculoGold transfection kit (PharMingen, San Diego, CA) according to the manufacturer's instructions. After initial transfection, working virus stocks were generated by three sequential virus amplifications. Sf9 cells were cultured in 250-ml disposable Erlenmeyer flasks at 28°C under rotation at 125 rpm in SF 900 II medium (Life Technologies, Inc.) supplemented with 5% (v/v) fetal calf serum (Gemini, Calabasa, CA) and 0.1 mg/ml gentamicin (Boehringer Mannheim, Mannheim, Germany). Cells were maintained at a density of 0.5-6.0 ϫ 10 6 cells/ml. For infection, cells were sedimented by centrifugation and suspended in fresh medium. Cells were seeded at 3.0 ϫ 10 6 cells and infected with a 1:100 dilution of baculovirus stocks. Cells were cultured for 48 h before membrane preparation.
HEK293 cells were cultured in high glucose Dulbecco's modified Eagle's medium (Life Technologies, Inc.) supplemented with 10% (v/v) fetal calf serum at 37°C and 5% (v/v) CO 2 . Cells were transfected with pcDNA 3.0 encoding human FPR by calcium phosphate precipitation. For selection of stably transfected cells, 0.5 mg/ml genticin (Life Technologies, Inc.) was added to the culture medium following transfection (47) . Antibiotic-resistant clones were isolated and assayed for expression of FPR by [ 3 H]FMLP binding (see below). Sf9Ϫ and HEK293 membranes were prepared as described (33) using 1 mM EDTA, 0.2 mM phenylmethylsulfonyl fluoride, 10 g/ml benzamidine, and 10 g/ml leupeptin as protease inhibitors.
[ H]FMLP by filtration through GF/C filters, followed by three washes with 2 ml of binding buffer (4°C). Filter-bound radioactivity was determined by liquid scintillation counting. SDS-PAGE and Immunoblot Analysis-SDS-PAGE was performed according to Laemmli (48) . Solubilized membrane proteins were separated on a gel containing 10% (w/v) acrylamide. Immunoblotting was performed according to Towbin et al. (49) . Nitrocellulose membranes were reacted with M1 antibody (1: 1000), anti-G i ␣ common antibody (1: 200), or anti-G␤ common antibody (1: 200). Immunoreactive bands were visualized by sheep anti-mouse IgG (M1 antibody) and donkey antirabbit IgG (anti-G i ␣ common and anti-G␤ common antibody), respectively, coupled to peroxidase, using o-dianisidine and H 2 O 2 as substrates.
Miscellaneous-Protein was determined using the Bio-Rad DC protein assay kit (Bio-Rad). Data were analyzed by non-linear regression, using the Prism program (GraphPad, Prism, San Diego, CA).
RESULTS

Co-expression of FPR with
MembranesMembranes from uninfected Sf9 cells and Sf9 cells triple-infected with FPR-, G i ␣ 2 -, and ␤ 1 ␥ 2 -encoding baculoviruses were prepared and subjected to immunological analysis with the M1 antibody, recognizing the N-terminal FLAG epitope of the FPR, anti-G i ␣ common antibody, and anti-G␤ common antibody. In baculovirus-infected Sf9 membranes, the M1 antibody recognized a broad and diffuse band with an apparent molecular mass of ϳ40 kDa, consistent with the expression of glycosylated FPR (Fig. 1A) . In uninfected Sf9 cells, no immunoreactivity with the M1 antibody was detected. The migration of the non-modified FPR expressed in Sf9 cells in SDS-PAGE (37) is similar to the migration of the FLAG epitope-and hexahistidine-tagged FPR. The FPR expressed in neutrophil membranes migrates as 50 -70-kDa protein in SDS-PAGE, indicating that glycosylation of the FPR in Sf9 cells is less extensive than in mammalian cells (50) .
The lack of specific immunoreactive bands recognized by anti-G i ␣ common antibody in uninfected Sf9 cells is indicative of the absence of mammalian-type G i -protein ␣-subunits in Sf9 cell membranes (Fig. 1B) . Similar data were obtained by Quehenberger et al. (37) , Leopoldt et al. (34) , and Grü newald et al. (51) . However, in Sf9 membranes from G i ␣ 2 baculovirus-infected cells, a strong immunoreactive 40-kDa band appeared, corresponding to the expected molecular mass of G i ␣ 2 (31, 52) . Of interest, Sf9 membranes express a G-protein ␤-subunit which is recognized by the anti-G␤ common antibody and possesses a molecular mass of 36 kDa (Fig. 1C) (34) . In Sf9 cells infected with ␤ 1 ␥ 2 baculovirus, an immunoreactive band migrating slightly faster, corresponding to ␤ 1 , appeared, whereas the expression of the insect ␤-subunit appeared to decrease. Collectively, our data show that structurally intact FPR, G i ␣ 2 , and ␤ 1 -subunit can be co-expressed in Sf9 cells. We did not assess the expression of the ␥ 2 -subunit in Sf9 cells, but the below-described data strongly indicate that functional G i ␣ 2 ␤ 1 ␥ 2 heterotrimers were formed.
The FPR Couples Efficiently to G i ␣ 2 ␤ 1 ␥ 2 but Not to Endogenous G-proteins in Sf9 Membranes-Quehenberger et al. (37) had shown that the human FPR can be expressed in Sf9 cells but that the GPCR does not couple to the endogenous G-proteins of the insect cells as assessed by the lack of formyl peptide-stimulated GTPase activity and GTP␥S binding and the lack of high affinity agonist binding. In accordance with these data, basal GTP␥S binding in Sf9 membranes expressing FPR alone was low, and FMLP increased this GTP␥S binding only marginally (Fig. 2) . The expression of FPR together with G i ␣ 2 or ␤ 1 ␥ 2 did not induce significant increases in basal GTP␥S binding and did not result in the appearance of a large stimulatory effect of FMLP. These data clearly show that the FPR cannot form a functional complex with mammalian G i ␣ 2 plus insect ␤␥ complexes or insect G-protein ␣-subunits plus mammalian ␤ 1 ␥ 2 complex. However, the co-expression of FPR together with G i ␣ 2 ␤ 1 ␥ 2 strongly increased basal GTP␥S binding. FMLP further increased this high GTP␥S binding, whereas CsH efficiently reduced basal GTP␥S binding. These data show that the FMLP-liganded FPR can productively activate G i ␣ 2 ␤ 1 ␥ 2 . Most intriguingly, the high basal GTP␥S binding in the complete co-expression system appeared to be largely mediated by the agonist-free FPR since CsH strongly suppressed basal GTP␥S binding. These data were our first evidence that the FPR expressed in Sf9 membranes is constitutively active and that CsH is an inverse FPR agonist.
The inhibitory effect of PTX on basal G-protein activity in HL-60 membranes provided circumstantial evidence for constitutive FPR activity (29 -31) . Based on these results, we expected PTX also to reduce basal GTP␥S binding in Sf9 mem- branes expressing FPR plus G i ␣ 2 ␤ 1 ␥ 2 . We treated Sf9 cells with PTX (300 ng/ml) for 24 h before membrane preparation. In HL-60 cells, these conditions are suitable to completely block FMLP-stimulated GTP␥S binding (31) . However, in membranes obtained from PTX-treated Sf9 cells, there was neither a reduction of basal GTP␥S binding nor FMLP-stimulated GTP␥S binding compared with control membranes (data not shown). We assume that PTX only poorly penetrates the plasma membrane of Sf9 cells so that the number of non-ADPribosylated G i ␣-subunits is still high enough to allow virtually unimpaired coupling of FPR to G i ␣ 2 ␤ 1 ␥ 2 . This assumption is supported by the fact that for ADP-ribosylation of endogenous PTX-sensitive G-proteins of Sf9 cells, PTX had to be employed at extremely high concentrations (53) . To the best of our knowledge, a successful PTX treatment of intact Sf9 cells expressing a mammalian GPCR and mammalian G-protein has not yet been reported.
Time course of GTP␥S Binding: FMLP Accelerates While CsH Delays Association of GTP␥S to
Membranes-GTP␥S binding to G-proteins is quasi-irreversible and follows monophasic saturation kinetics (30) . In Sf9 membranes expressing FPR plus G i ␣ 2 ␤ 1 ␥ 2 , basal GTP␥S binding proceeded with a t1 ⁄2 of 17 min, and a maximum was reached after ϳ60 min (Fig. 3) . FMLP increased the association rate of GTP␥S by more than 3-fold (t1 ⁄2 , 5 min). The relative stimulatory effect of FMLP was most pronounced at early time points (e.g. 145% stimulation at 5 min), whereas at later time points, the stimulatory effect of FMLP became smaller (e.g. only 20% stimulation at 180 min). In contrast to FMLP, CsH delayed the association rate of GTP␥S by more than 2-fold (t1 ⁄2 , 36 min), and the inhibitory effect of CsH was pronounced even at late time points of the binding reaction (e.g. 32% inhibition at 180 min versus 50% inhibition at 30 min).
The (Fig. 4A) . GTP␥S uncouples GPCR from G-proteins by activating G-protein ␣-subunits. As a result of this uncoupling, agonist affinity for GPCR is reduced (14, 22, 29, 33 (11, 54) . Thus, we conclude that the high constitutive activity of the FPR expressed in Sf9 cells cannot be explained by GPCR overexpression.
Unaltered Ligand Binding Affinities of the FLAG-and Hexahistidine Tag-modified FPR in Sf9 Membranes-We introduced an N-terminal FLAG epitope and a C-terminal hexahistidine tag into the FPR (see "Experimental Procedures") to facilitate immunological detection (see Fig. 1A ) and future purification (20, 45) (11, 54) . We also determined the affinities of BocPLPLP and CsH for the FLAG-epitope-and hexahistidine-tag-modified FPR. BocPLPLP and CsH inhibited [
3 H]FMLP binding to the receptor according to monophasic functions (Fig. 4B) . The K i value for CsH at the FLAG epitope-and hexahistidine-tagmodified FPR-26 was 287 Ϯ 18 nM, and at the native FPR the K i value is 100 nM (10, 11). The corresponding values for Boc-PLPLP at the modified and native FPRs are 1.50 Ϯ 0.19 and 1.46 M, respectively (10, 11) . Taken together, all these data show that the ligand binding properties of the FPR expressed in myeloid cells and those of the FLAG epitope-and hexahistidine-tag-modified FPR expressed in Sf9 cells are very similar. Previous studies with other GPCRs have also shown that the FLAG-and hexahistidine-tag modifications do not interfere with receptor ligand binding properties (45, 46, 55) . Additionally, a hexahistidine tag may decrease susceptibility of GPCR to proteolysis (46) . Since proteolysis of GPCRs expressed in Sf9 cells can be a serious problem (56) , protection against proteolysis by a tag is an important advantage for accurate data analysis. In fact, we did not detect degradation products of the FPR in immunoblots (see Fig. 1A ).
GTP␥S Saturation Binding Studies: a Single FPR Molecule Activates ϳ7 G i ␣ 2 ␤ 1 ␥ 2 Heterotrimers in Sf9 Membranes-The observed constitutive activity of the FPR expressed in Sf9 cells could be the result of an abnormal GPCR to G-protein ratio. Specifically, if the number of available G-proteins per FPR molecule in Sf9 membranes were increased relative to physiological conditions, the fraction of receptors in the R* state would increase and, thereby, enhance inverse agonist efficacy (17, 18, 27) . By determining the maximum FMLP-stimulated GTP␥S binding in HL-60 membranes and referring this number to the expression level of G-protein-coupled FPRs, Gierschik et al. (30) and Jacobs et al. (54) estimated that one FPR molecule can activate 4 -20 G i -proteins. At an incubation time of 45 min, i.e. a time suitable to detect both agonist stimulation and inverse agonist inhibition of GTP␥S binding (see Fig. 3 ), the B max of FMLP-stimulated GTP␥S binding amounted to 2.83 Ϯ 0.18 pmol/mg, and the B max of CsH-inhibited GTP␥S binding was 3.03 Ϯ 0.22 pmol/mg. Thus, the total concentration of FPR-regulated G i ␣ 2 ␤ 1 ␥ 2 heterotrimers in Sf9 membranes was 5.85 pmol/mg (Fig. 5) . If this number is divided by the expression level of G-protein-coupled FPRs (0.84 pmol/mg) (see 4A ), one can estimate that one FPR molecule activates 5-7 G i -proteins. This number compares favorably to the data obtained in HL-60 membranes (30, 54) . About 50% of the FPRinduced G-protein activation in Sf9 membranes is mediated by the agonist-free GPCR, and the remainder is mediated by the agonist-occupied FPR. Taken together, our data show that increased availability of G-proteins in the Sf9 membranes does not explain the observed constitutive activity of the FPR. The K d value of the FMLP-stimulated GTP␥S binding was 0.78 Ϯ 0.36 nM, and the K d value of the CsH-inhibited GTP␥S binding was not significantly different.
Concentration-Response Curves for FMLP, CsH, and BocPL-PLP on GTP␥S Binding in Sf9 Membranes: CsH Is an Inverse FPR Agonist and BocPLPLP Is a Neutral FPR Antagonist-FMLP stimulated GTP␥S binding in membranes expressing
FPR plus G i ␣ 2 ␤ 1 ␥ 2 with a half-maximal effect at 0.82 Ϯ 0.12 M and a plateau at 10 -100 M (Fig. 6A) . Similar values were obtained for the FMLP-induced G i -protein activation in HL-60 membranes (31, 54, 57) . CsH reduced GTP␥S binding with a half-maximal effect at 36 Ϯ 19 nM and a plateau at 1-10 M. Of interest, the potency of CsH at reducing basal GTP␥S binding was almost 8-fold higher than its K i value for inhibition of [ 3 H]FMLP binding (see Fig. 4B ). In contrast, the potency of FMLP at stimulating GTP␥S binding was more than 200 times lower than the K d value for [ 3 H]FMLP binding (see Fig. 4A ). These apparent discrepancies could be reconciled when taking into consideration that guanine nucleotides reciprocally alter the affinities of agonist and inverse agonist for GPCR (22, 58) and that ligand competition studies were performed in the absence of guanine nucleotides, whereas GTP␥S binding studies were performed in the presence of guanine nucleotides (GTP␥S and GDP) (see "Experimental Procedures"). In particular, GDP and GTP␥S both reduce the affinity of FPR for agonist (59) , whereas guanine nucleotides increase the affinity of GPCR for inverse agonist, presumably by facilitating stabilization of GPCR in the G-protein-uncoupled R state (22, 58) .
In contrast to CsH, BocPLPLP at concentrations up to 3 M, e.g. a concentration twice as high as its K i value for binding to the FPR (see Fig. 4B ), had no inhibitory effect on basal GTP␥S binding (Fig. 6A) . At a concentration of 10 M, BocPLPLP had a small inhibitory effect on GTP␥S binding. However, if Boc-PLPLP, by analogy to CsH, had been an inverse FPR agonist, the peptide would have been expected to reduce GTP␥S binding with a potency that is higher than its K i value for binding to the FPR. Most likely, the small inhibition of basal GTP␥S binding by BocPLPLP at 10 M represents a nonspecific effect of this extremely hydrophobic peptide on G i -proteins rather than a specific FPR-mediated effect. Indeed, several hydrophobic peptides have been shown to inhibit the function of PTX-sensitive G-proteins directly (60) .
According to the two-state model of GPCR activation, neutral antagonists do not only block the effects of agonists but also the effects of inverse agonists (18, 22, 23) . Because BocPLPLP at concentrations of up to 3 M did not affect basal GTP␥S binding, we could study the effect of the antagonist on CsH-mediated inhibition of GTP␥S binding. In fact, BocPLPLP at 3 M shifted the concentration-response curve for CsH on GTP␥S binding by 3-fold to the right (Fig. 6B) . As reported previously for human neutrophils and dibutyryl cAMP-differentiated HL-60 cells (10, 11), BocPLPLP also competitively antagonized the stimulatory effect of FMLP in the Sf9 cell system (data not shown).
Regulation of GTP␥S Binding in Sf9 Membranes by NaCl and KCl: Na
ϩ Stabilizes the FPR in the R State and Thereby Reduces the Inverse Agonistic Efficacy of CsH-NaCl efficiently reduces the basal G-protein activity in membranes expressing constitutively active G i -protein-linked GPCRs (26, 32) . As the result of this reduction in basal G-protein activity by NaCl, the efficacy of inverse agonist is reduced (26, 32) . Of interest, NaCl also efficiently reduces the basal G-protein activity in myeloid membranes expressing FPR (29, 30) . These findings prompted us to analyze the effects of NaCl on GTP␥S binding in Sf9 membranes expressing FPR plus G i ␣ 2 ␤ 1 ␥ 2 . NaCl reduced basal GTP␥S binding to a value that corresponds to maximum CsHinhibited GTP␥S binding, i.e. NaCl reduced the inverse agonistic efficacy of CsH (Fig. 7A) . In contrast, NaCl increased the absolute and relative stimulatory effect of FMLP on GTP␥S binding. Note that KCl at concentration as high as 150 mM could not abolish the inhibitory effect of CsH on GTP␥S binding (Fig. 7B) .
The differential effects of NaCl and KCl on basal GTP␥S binding in Sf9 membranes clearly show that the potent inhibition caused by NaCl is not due to an increase in ionic strength of the incubation medium or due to Cl Ϫ anions but rather due to Na ϩ cations. The fact that Na ϩ abolished the inhibitory effect of CsH on GTP␥S binding while leaving intact the total FPR ligand-regulated GTP␥S binding, i.e. the difference between maximum CsH-inhibited and maximum FMLP-stimulated GTP␥S binding, suggests that both Na ϩ and CsH stabilize the FPR in the R state. Considering mutational studies with other GPCRs (61) (62) (63) , it is likely that the highly conserved Asp-71 in the second transmembrane domain of the FPR (64) represents an important molecular target of Na ϩ . Of interest, the inhibitory effect of NaCl on basal GTP␥S binding was half-maximal at a concentration as low as 5 mM and reached a maximum already at 20 -50 mM. In this context, it should be noted that the intracellular free Na ϩ concentration in unstimulated human neutrophils is ϳ10 mM and rises up to ϳ20 mM upon stimulation with FMLP (65) . The similarities of the intracellular Na ϩ concentration with the Na ϩ concentrations that regulate FPR activity in vitro raise the question inasmuch as Na ϩ influx could provide a signal by which the constitutive activity of the FPR is decreased. However, it is unknown whether in vivo, Na ϩ has free access to the intramembranously buried Asp-71 of the FPR. It is also unknown whether Na ϩ reaches Asp-71 from the intracellular space, from the extracellular space, or from both compartments.
Studies with HEK293 Membranes-The glycosylation pattern of the FPR expressed in mammalian and insect cells is quite different (Fig. 1A) (37, 50) . To address the question of whether the glycosylation pattern of the FPR or the cellular background critically determine constitutive GPCR activity, we also expressed the FPR in HEK293 cells. This mammalian expression system is suitable for reconstituting G i -protein coupling of chemoattractant receptors (38, 39) . For our studies, we chose a cell clone that stably expressed FPR with a B max of 1.11 pmol/mg, i.e. a level comparable to the FPR expression level in Sf9 cells and HL-60 cells (Fig. 4A) (11, 54 (Fig. 4A) (11, 54) .
To study the G-protein coupling of the FPR expressed in HEK293 membranes, we performed GTP␥S binding studies (Table I ). In the absence of NaCl, FMLP did not exhibit a stimulatory effect on GTP␥S binding, whereas CsH reduced basal GTP␥S binding by about 20%. NaCl (100 mM) reduced basal GTP␥S binding in HEK293 membranes by almost 50% and unmasked a robust stimulatory effect of FMLP on GTP␥S binding. In contrast, NaCl abolished the inhibitory effect of CsH on GTP␥S binding in HEK293 membranes. Overall, the ligand and Na ϩ regulation of GTP␥S binding by FPR in HEK293 membranes is similar to the regulation observed in Sf9 membranes. Of interest, the apparent constitutive activity of the FPR expressed in HEK293 cells is even higher than in Sf9 membranes since FMLP failed to stimulate GTP␥S binding in HEK293 membranes in the absence of NaCl. However, it should be noted that the absolute ligand-regulated GTP␥S binding in HEK293 membranes is substantially lower than in Sf9 membranes (compare Fig. 7 with Table I , for example). In addition, the relative inhibitory effect of CsH on GTP␥S binding in HEK293 membranes was considerably smaller than in Sf9 membranes (ϳ20% inhibition versus ϳ50% inhibition). This difference between the two expression systems may indicate that in HEK293 cells, the concentration of G-proteins that can couple to the FPR is lower than in Sf9 cells. From a practical point of view, our data clearly show that the Sf9 system is more sensitive than the HEK293 system for analysis of constitutive FPR activity on the membrane level. However, HEK293 membranes are still more sensitive in this respect than dibutyryl cAMP-differentiated HL-60 membranes since, in the latter system, inverse agonistic activity of CsH could not be detected at all (11). 
DISCUSSION
High Constitutive Activity of the Human FPR: Implications for Other Chemoattractant Receptors and Structural Basis-
Our data can be interpreted in the framework of the two-state model of GPCR activation (14 -17, 20, 21) . Specifically, the FPR isomerizes from an inactive state R to an active R* state, and this isomerization occurs at a substantial rate even in the absence of agonist. The spontaneous RϪ to R* transition results in high basal GTP␥S binding (Fig. 8A) . FMLP stabilizes the FPR in the R* state and, thereby, increases basal GTP␥S binding to G i ␣ 2 ␤ 1 ␥ 2 in Sf9 membranes (Fig. 8B) , whereas CsH and Na ϩ stabilize the FPR in the R state and reduce the high basal GTP␥S binding (Fig. 8C) . The neutral antagonist BocPL-PLP inhibits both the effects of agonist (Fig. 8B ) and inverse agonist (Fig. 8C) . Taken together, the FPR is the first member of the chemoattractant receptor family (4, 66) unequivocally identified as being constitutively active.
We can exclude the possibility that the constitutive activity of the FPR is attributable to receptor overexpression or excessive availability of G-proteins (Figs. 4A and 5 and Table I ). Moreover, we observed constitutive FPR activity in a mammalian and an insect expression system, excluding the possibility that differences in cellular background or glycosylation have a profound impact on constitutive GPCR activity. Thus, it appears that the constitutive activity of the FPR observed in two unrelated and very different expression systems reflects an authentic property of this GPCR.
Indeed, constitutive activity has been described for numerous wild-type GPCRs including biogenic amine receptors (e.g. ␤ 2 , hydroxytryptamine 2C , and histamine H 2 receptors) (17, 19 -23, 36) , neuropeptide (␦-opioid) receptors (24, 32, 67) , muscarinic (28, 68) , and thyrotropin receptors (25) . Of interest, the constitutive activity of individual GPCRs differs substantially from each other. For example, the thyrotropin receptor has a much higher constitutive activity than the luteinizing/chorionic gonadotropin receptor, although the two GPCRs are highly homologous (25) . Given the fact that at a physiologically relevant receptor expression level and receptor to G-protein stoi- 4A and 5 and Table I ), the maximum effect of inverse agonist was of similar magnitude as, or even bigger than, the maximum effect of agonist, the FPR can certainly be classified as a highly constitutively active GPCR. Considering that the FPR shows substantial homology to the complement C5a, the platelet-activating factor, and leukotriene B 4 receptors (4, 69 -71) , it is likely that these chemoattractant receptors possess at least some constitutive activity as well.
Our data raise the question of what the structural basis of the constitutive FPR activity may be. So far, a common structural motif in GPCRs resulting in constitutive activity has not yet been identified. It rather appears than in different GPCR families, different receptor domains are of importance for constraining GPCR in an inactive and agonist-activable conformation (72) . Based on the Na ϩ sensitivity of the constitutive FPR activity and Na ϩ sensitivity data obtained for other GPCRs (61-64), Asp-71 in the second transmembrane domain of the FPR may play a role in regulating the R to R* transition of this GPCR. Of particular interest, a chimeric FPR in which the first intracellular loop of the FPR is replaced by the corresponding domain of the C5a receptor possesses a higher constitutive activity than wild-type FPR (73) . These findings point to the importance of the first cytosolic loop of the FPR in constraining this GPCR in an inactive conformation and support our suggestion that other members of the chemoattractant receptor family may also be constitutively active, perhaps even more constitutively active than the FPR. Since the first cytosolic loop of the FPR is important for receptor/G-protein coupling (74) , it is conceivable that structural changes in this region of the receptor molecule affect the ability of the G-protein to interact with GPCR and, consequently, to stabilize the R* state. Thus, the first cytosolic loop of the C5a receptor may be more efficient at promoting receptor/G-protein coupling than than the corresponding FPR domain so that G-protein can more efficiently stabilize the R* state and, thereby, increase the apparent constitutive GPCR activity (18, 33) . In this context, it is important to note that the first cytosolic loop is also involved in constitutive activation of the melanocyte-stimulating hormone receptor (75) and the parathyroid hormone-parathyroid hormone-related peptide receptor (76) . The third transmembrane domain of the FPR may also be of importance for determining constitutive GPCR activity (see discussion below).
Possible Biological Roles of Constitutive FPR Activity-CsH is a naturally occurring inverse agonist. This raises the question of whether these compounds could have any biological function. CsH is a metabolite of the fungus imperfectus T. inflatum Gams which resides in the soil of Wisconsin and the Hardanger Vidda (Norway) (13) . Because of its structural similarity to cyclosporin A, CsH is likely to be absorbed in the gastrointestinal tract after oral ingestion (11) . Thus, CsH could reach the systemic circulation of mammals feeding on roots, worms, and insects present in the soil and exert biological effects on neutrophils.
Evidence for the relevance of constitutive activity of wildtype GPCRs in intact cells has already been provided for the 5-hydroxytryptamine 2C receptor (22) , ␤-adrenergic receptors (77, 78) , muscarinic receptors (79), and ␣ 1 -adrenoreceptors (80) . Several pieces of evidence point to the relevance of constitutive FPR activity in intact cells. First, in intact myeloid cells, inhibitory effects of PTX on "basal" activities have been repeatedly observed. Specifically, PTX reduces basal inositol phosphate production in human neutrophils and HL-60 cells (81, 82) , Na ϩ -dependent uridine uptake in HL-60 cells (83) , and basal Na ϩ entry in rabbit neutrophils (84) . It should also be mentioned that PTX can inhibit apparently agonist-independent long term events in HL-60 cells such as Me 2 SO-induced differentiation (85). Second, the expression level of FPR is increased by mediators of inflammation such as interferon-␥ and tumor necrosis factor-␣ (86, 87) . Increased FPR expression increases the absolute number of FPRs in the R* state and, thereby, could reduce the treshold concentration of FMLP at which neutrophils generate reactive oxygen species and release lysosomal enzymes ("priming") (3). Third, elevated basal phospholipase C activity has been observed for the FPR co-expressed with the PTX-insensitive G-protein G␣ 16 in COS-7 cells (73) .
Why Can the Inverse Agonistic Activity of CsH at the FPR Not be Detected in HL-60 Membranes?-Dibutyryl cAMP-differentiated HL-60 cells are a very sensitive model system for studying FPR/G i -protein interaction (7) . Nonetheless, in our previous study (11) we failed to uncover an inhibitory effect of CsH on basal G i -protein activity in this system, and we concluded that CsH is a neutral FPR antagonist. Our present data show that CsH must be classified as an inverse agonist. We can offer two explanations which alone or together could to reconcile the divergent effects of CsH in our previous and our present study.
First, dibutyryl cAMP-differentiated HL-60 cells express two different FPR subtypes, referred to as FPR-26 and FPR-98, respectively (40) . In our present study, we analyzed FPR-26 (see "Experimental Procedures"). The precise ratio of FPR-26 and FPR-96 in HL-60 cells is unknown. FPR-26 and FPR-98 differ from each other in two amino acids, namely at positions 101 and 346 (40) . These amino acid positions are located in the third transmembrane domain of the receptor and the receptor C terminus, respectively. Both receptor regions are presumably not critical for G-protein coupling (74) . However, considering the fact that mutations in the third transmembrane domain of certain GPCRs, i.e. in ␣ 1 -adrenergic and thyrotropin receptors (72) , can lead to increases in constitutive activity, it cannot be excluded that FPR-26 and FPR-98 exhibit different degrees of constitutive activity. An implication of any difference in constitutive activity of FPR isoforms would be that dibutyryl cAMPdifferentiated HL-60 cells predominantly express an FPR isoform with low constitutive activity. Based on our current results, this should be the FPR-98.
Second, dibutyryl cAMP-differentiated HL-60 cells express at least eight different types of G i -protein-linked GPCRs (FPR-26, FPR-98, P 2U receptors, histamine H 1 receptors, and receptors for C5a, platelet-activating factor, leukotriene B 4 , and sphingosylphosphorylcholine) (7, 40, 88) all of which may exhibit some degree of constitutive activity. In fact, studies with FPR/C5a receptor chimeras support the view that not only FPRs but also other chemoattractant receptors are constitutively active (73) . PTX reduces the basal G i -protein activity in membranes of dibutyryl cAMP-differentiated HL-60 cells by 20 -40% (31, 57) . Thus, the relative contribution of FPRs to the total basal G i -protein activity supported by all constitutively active GPCR types in HL-60 membranes may be too small and beyond the sensitivity limit of the available G-protein assays to detect an effect of CsH. In contrast to HL-60 membranes, Sf9 membranes and HEK293 membranes express a single defined GPCR subtype, thereby eliminating the contribution of other GPCRs on basal G-protein activity and greatly increasing the assay sensitivity.
In conclusion, we have shown that the human FPR expressed in Sf9 cells and HEK293 cells possesses high constitutive activity. CsH is an inverse FPR agonist and, like Na ϩ , stabilizes the FPR in the inactive R state. Constitutive FPR activity is probably of importance in vivo.
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